We are pleased to inform you about our new investment: Bioceltix.
Bioceltix Sp. z o. o. develops innovative biological drugs based on stem cells, intended for companion animals. According to forecasts, by 2020 the share of biological medicines in the entire pharmaceutical market will increase up to 28%. This means USD 390 billion for biological therapies.
Strategic activities of Bioceltix include the organization of the cGMP plant based on an isolated line for the production of veterinary biological drugs based on stem cells in a pharmaceutical standard. The company conducts an individual dialogue with the European Medicines Agency as part of the scientific advice procedure – the purpose of the talks is to approve the full registration path of the first BCX-CM-J drug.
More information at http://bioceltix.com/o-firmie/